🧫
P2RY12 regulation of autophagy in VSMCs
active
experiment
Created: 2026-04-04T05:26:15
By: etl-v1-backfill
Quality:
50%
✓ SciDEX
ID: exp-f90ceea7-76be-4e57-80d0-981b67b113f8
🧫 Experiment Protocol
ExploratoryatherosclerosisP2RY12, ATG5cultured VSMCsproposed
This experiment investigated how P2RY12 receptor activation affects autophagy in vascular smooth muscle cells. The researchers examined MAP1LC3/LC3 maturation, SQSTM1 degradation, and autophagosome formation using various molecular techniques. They used transmission electron microscopy to visualize autophagic structures and performed Western blot analysis for autophagy markers. The study also included genetic knockdown of essential autophagy gene ATG5 to confirm the role of autophagy in P2RY12-mediated effects.
PRIMARY OUTCOME
autophagy activity assessment
EXPECTED OUTCOMES
Quantitative predictions: (1) 2-MeSADP treatment: LC3-II/I ratio decreases to 0.3-0.4 (baseline ~0.6-0.8), indicating reduced autophagosome formation. p62 accumulates 2-3 fold (reduced autophagic flux). (2) With bafilomycin: LC3-II accumulation is blunted in 2-MeSADP group vs. vehicle (indicating reduced autophagosome formation, not just increased clearance). (3) TEM: Autophagosomes reduced from 3-5 per cell (vehicle) to 1-2 per cell (2-MeSADP, p<0.01). (4) Ticagrelor rescues autophagy: LC3-II/I returns to 0.7-0.9, p62 to baseline. (5) ATG5 knockdown abolishes LC3-II formation and blocks any differences between treatment groups. (6) Rapamycin induces LC3-II/I to 1.2-1.5 regardless of P2RY12 status (validates assay sensitivity).
SUCCESS CRITERIA
Primary: P2RY12 agonist reduces LC3-II/I ratio by >40% compared to vehicle (p<0.01, one-way ANOVA). Secondary: (1) p62 accumulation >2-fold with agonist (p<0.05). (2) TEM autophagosome count reduced >40% (p<0.05, Mann-Whitney U test). (3) Antagonist rescues LC3-II/I to >80% of vehicle levels. (4) ATG5 knockdown eliminates LC3-II signal (<10% of control) and abolishes treatment effects (no significant difference between groups, p>0.1). (5) Bafilomycin flux assay: ΔLC3-II (bafilomycin - vehicle) reduced >50% in agonist group. Required reproducibility: Effect direction consistent in 3/3 independent experiments, p<0.05 in combined analysis.
PROTOCOL
Cells: Primary human aortic SMCs (HASMCs, Lonza) passages 4-7, cultured in SmGM-2 medium. Cholesterol loading: 50 μg/mL AcLDL for 48h. Treatments: (1) 2-MeSADP (P2RY12 agonist, 10 μM, 24h). (2) Ticagrelor (P2RY12 antagonist, 10 μM). (3) Bafilomycin A1 (100 nM, 4h) to block autophagosome-lysosome fusion. (4) Rapamycin (100 nM, positive control for autophagy induction). Autophagy markers: Western blot for LC3-I/II (anti-LC3B, 1:1000), SQSTM1/p62 (1:2000), ATG5 (1:1000), β-actin loading control. Quantify LC3-II/I ratio and p62 levels by densitometry. n=4 independent experiments. TEM: Fix cells in 2.5% glutaraldehyde, embed in resin, cut 70 nm sections, stain with uranyl acetate/lead citrate. Count autophagosomes (double-membrane vesicles with cytoplasmic content) per cell profile. Analyze 30-50 cells per condition. ATG5 knockdown: siRNA (Santa Cruz sc-41445, 50 nM, 48h), verify >70% knockdown. Controls: (1) Scrambled siRNA. (2) Vehicle (DMSO). (3) Bafilomycin to distinguish autophagy induction vs. reduced degradation. (4) Untreated baseline.
LINKED HYPOTHESES
Source: PMID 32160082 ↗
🧫 Experiment Extras
PATHWAY
autophagy pathway
MARKET PRICE
$0.50
STATUS
proposed
▸Metadataorigin_type: v1_polymorphic_backfill
| origin_type | v1_polymorphic_backfill |
| source_table | experiments |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.